Hyaluronic acid - Chugai Pharmaceuticals

Drug Profile

Hyaluronic acid - Chugai Pharmaceuticals

Alternative Names: NRD-101; Sodium hyaluronate - Chugai Pharmaceuticals; Suvenyl; Suvenyl Dispo

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Adjuvants; Antirheumatics; Eye disorder therapies; Glycosaminoglycans; Urologics
  • Mechanism of Action Hyaluronic acid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain
  • Discontinued Plantar fasciitis

Most Recent Events

  • 10 Mar 2017 Chugai Pharmaceutical plans a phase III trial for Pain in patients with knee osteoarthritis in Japan (NRD204CN; JapicCTI-173531)
  • 08 Jun 2016 Chemical information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top